

IDS 8/29/06

Sheet 1 of 1

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. 10/608,626		
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Kelsey et al.			
				Filing Date 27 Jun 2003	Group 1643		
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
HS ↓ HS	*354	2003/0086924A1	08.05.03	Sliwkowski, M.			
	*355	2004/0013667A1	22.01.04	Kelsey et al.			
	*356	2005/0208043A1	22.09.05	Adams et al.			
	*357	2005/0238640A1	27.10.05	Sliwkowski, M.			
	*358	2006/0034842A1	16.02.06	Adams et al.			
	*359	2006/0073143A1	06.04.06	Adams et al.			
	*360	2006/0083739A1	20.04.06	Sliwkowski, M.			
	*361	6,949,245B1	27.09.05	Sliwkowski, M.			
	*362	7,041,292B1	09.05.06	Sliwkowski, M.			
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)							
HS	363	Agus et al., "A potential role for activated HER-2 in prostate cancer" <u>Seminars in Oncology</u> 27(6 Suppl 11):76-83 (Dec 2000)					
	364	Agus et al., "Clinical Activity in a Phase I Trial of HER-2-Targeted rhuMAB 2C4 (pertuzumab) in Patients with Advanced Solid Malignancies (AST)" <u>Proceedings of the American Association for Cancer Research</u> (Abstract No. 771) 22:192 (2003)					
	365	Agus et al., "Clinical Activity in a Phase I Trial of HER2-Targeted rhuMAB 2C4 (pertuzumab) in Patients with Advanced Solid Malignancies" (Slides presented at the 2003 ASCO Annual Meeting) pps. 1-32 (2003)					
	366	Gilbertson, R.J., "Expression of ErbB-Neuregulin Signaling Network during Human Cerebellar Development: Implications for the Biology of Medulloblastoma" <u>Cancer Research</u> 58:3932-3941 (Sep 1, 1998)					
	367	Gilbertson, R.J., "Prognostic Significance of HER2 and HER4 Coexpression in Childhood Medulloblastoma" <u>Cancer Research</u> 57:3272-3280 (Aug 1, 1997)					
	368	Gilbertson, R.J., "The ErbB2 receptor represents a potential target for novel therapies in childhood medulloblastoma" <u>Clinical Cancer Research</u> (Abstract #38) 5(Suppl.):3737s (Nov 1999)					
	369	Gordon et al., "Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status" <u>Journal of Clinical Oncology</u> (Abstract #5051 from the 41st Annual Meeting of ASCO) 23(16S):467s (Jun 1, 2005)					
↓	370	Gordon et al., "Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer and the role of HER2 activation status" (Poster #5051 from the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO)) (May 15, 2005)					
HS	371	Grossi, P.M., "Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer" <u>Clinical Cancer Research</u> 9:5524-5529 (Nov 15, 2003)					
Examiner /Hong Sang/ (09/15/2006)				Date Considered 09/15/2006			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.